Study Summary
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell leukemia.
Want to learn more about this trial?
Request More InfoInterventions
CD19/CD20 Dual-CAR-T cellsBIOLOGICAL
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei Yanda Ludaopei Hospital | Sanhe | Hebei | China |